罗基诺林:一种潜在的神经保护性化合物,用于针对新陈代谢的神经退行性疾病
Alessio Canovai1, Pete A Williams2
1Department of Biology, University of Pisa, Pisa, Italy.
Neural regeneration research
|May 20, 2024
概括
罗基诺林 (PQQ) 是一种对哺乳动物健康至关重要的饮食化合物,支持繁殖,生长和免疫力. PQQ调节新陈代谢和线粒体功能,在神经退行性疾病中显示出潜在的神经保护性益处.
科学领域:
- 生物化学 生物化学
- 营养科学 营养科学
- 细胞生物学 细胞生物学
背景情况:
- 罗基诺林 (PQQ) 作为细菌脱酶的辅因子起作用.
- PQQ在饮食来源中发现,可以口服补充.
- 饮食中缺少PQQ会导致哺乳动物生殖,生长和免疫方面的缺陷.
研究的目的:
- 为了回顾PQQ的一般性质.
- 分析PQQ在调节代谢和线粒体机制中的作用.
- 研究PQQ在神经退行性疾病中的神经保护作用.
主要方法:
- 对PQQ的生理和病理作用的文献综述.
- 对研究PQQ对新陈代谢和神经退行作用的实验模型的分析.
- 对PQQ的健康益处进行当前研究的综合.
主要成果:
- PQQ调节细胞信号通路,促进新陈代谢和线粒体过程.
- PQQ显示了改善与功能失调的新陈代谢和线粒体活动相关的临床缺陷的潜力.
- 在各种实验性神经退行模型中,PQQ表现出神经保护性质.
结论:
- PQQ是哺乳动物生命的重要化合物,影响关键的代谢和线粒体功能.
- PQQ对治疗代谢功能障碍和线粒体损伤相关的疾病具有前景.
- 需要进一步的研究来充分阐明PQQ在神经保护中的机制及其潜在的治疗应用.
更多相关视频
相关概念视频
Parkinson's Disease: Treatment
261
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
261
Electron Transport Chain: Complex I and II
13.0K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
13.0K
The Electron Transport Chain
16.6K
The electron transport chain or oxidative phosphorylation is an exothermic process in which free energy released during electron transfer reactions is coupled to ATP synthesis. This process is a significant source of energy in aerobic cells, and therefore inhibitors of the electron transport chain can be detrimental to the cell's metabolic processes.
Inhibitors of the electron transport chain
Rotenone, a widely used pesticide, prevents electron transfer from Fe-S cluster to ubiquinone or Q...
Inhibitors of the electron transport chain
Rotenone, a widely used pesticide, prevents electron transfer from Fe-S cluster to ubiquinone or Q...
16.6K
Parkinson's Disease: Overview
528
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
528
Drugs Affecting Neurotransmitter Synthesis
1.4K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.4K
Alzheimer's Disease: Treatment
180
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
180


